Research and Markets (http://www.researchandmarkets.com/research/5628s9/opportunityanalyze)
has announced the addition of the "OpportunityAnalyzer:
Gout - Opportunity Analysis and Forecast to 2018" report to
Novel Therapies to Boost Gout Disease Treatment Market, but Physician
Education Needs to Be Improved
Thanks to the introduction of novel therapies in the near future, the
gout disease treatment market value will increase from $989 million in
2013 to $2.28 billion by 2018, at a significant Compound Annual Growth
Rate (CAGR) of 18.2%, forecasts research and consulting firm The authors.
Out of the six major markets (6MM: the US, France, Germany, Italy, Spain
and the UK), the US accounted for 90% of the 2013 gout treatment sales.
This was due to the wide use of Colcrys therapy, which is not
genericlly available in the US, as well as the high prevalence of gout
in the country.
The five European countries (5EU) are now experiencing a dramatic
increase in gout prevalence, which is 2.3 times faster than in the US.
By the end of the forecast period, The authors expects the 5EU to have a
market share of 12.5%.
Valentina Gburcik, Ph.D., The authors's Analyst covering Cardiovascular
& Metabolic Disorders, says: With the recent approval of the powerful
anti-inflammatory therapy Ilaris, and the market entry of two novel
urate-lowering therapies, lesinurad and ulodesine, physicians will have
more options available to tackle difficult-to-treat gout.
However, Gburcik says that despite advances in gout disease treatment,
physician education remains the greatest unmet need in the gout
The analyst continues: The standard treatments are effective in most
gout patients, therefore making gout a potentially curable disease.
However, there is a growing number of patients for whom the standard
therapies are inappropriate.
Since most physicians still do not take gout seriously enough, they are
passing on this attitude to their patients, who are consequently unaware
of the importance of keeping their urate levels down and are not
sticking to the appropriate therapy. This in turn is leading to an
increase in the difficult-to-treat patient pool, Gburcik concludes.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
5 Current Treatment Options
6 Unmet Needs Assessment and Opportunity Analysis
7 Research and Development Strategies
8 Pipeline Assessment
9 Pipeline Valuation Analysis
For more information visit http://www.researchandmarkets.com/research/5628s9/opportunityanalyze
[ Back To NFVZone's Homepage ]